GlassScriptPhysician profile
Daven Scott Smith
NPI 1538808746
$6,659.87
in general payments reported to CMS, 2019-2025
28 companies · $3,484 in 2025
The $3,484 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $3,176 · 2025: $3,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,630 · Education: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,629.87 |
| Education | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,468.06 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $858.02 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $698.63 | 2024-2025 | Tremfya, Stelara |
| Aimmune Therapeutics, INC. | $433.90 | 2024-2025 | Zenpep, Vowst |
| Madrigal Pharmaceuticals | $369.73 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $355.32 | 2024-2025 | Voquezna |
| Pfizer INC. | $345.63 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.65 | 2024-2025 | Trulance, Relistor, Xifaxan |
| Genzyme Corporation | $241.26 | 2024-2025 | |
| Gilead Sciences, INC. | $227.92 | 2024-2025 | |
| Ardelyx, INC. | $226.02 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $191.14 | 2024-2025 | Vegzelma, Zymfentra |
| Regeneron Healthcare Solutions, INC. | $174.95 | 2024-2025 | Dupixent |
| Organon LLC | $124.65 | 2024-2025 | Hadlima |
| Merck Sharp & Dohme LLC | $85.02 | 2024 | Dificid |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $72.60 | 2024-2025 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.63 | 2024 | Cyltezo |
| Intercept Pharmaceuticals, INC. | $70.19 | 2024-2025 | |
| Sandoz INC. | $63.73 | 2024-2025 | Hyrimoz |
| Enterra Medical, INC. | $60.07 | 2025 | |
| Fresenius Kabi USA, LLC | $52.93 | 2024 | Idacio |
| Ipsen Biopharmaceuticals, INC | $42.69 | 2024-2025 | Iqirvo |
| Boston Scientific Corporation | $41.43 | 2025 | Intracept |
| Qol Medical, LLC | $23.47 | 2024 | Sucraid |
| Sanofi-Aventis U.S. LLC | $20.79 | 2024 | |
| Daiichi Sankyo INC. | $15.52 | 2024 | Injectafer |
| Novo Nordisk INC | $15.39 | 2025 | Wegovy |
| Orphalan INC | $14.53 | 2025 | Cuvrior |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daven Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.